Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.prro.2011.04.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial Comment: Radiation Dose in Contrast-Enhanced Mammography-Implications for Screening Protocols.
AJR Am J Roentgenol
January 2025
The University of Alabama at Birmingham, Birmingham, AL 35233.
Performance Tests for Automation Routines in Radiology.
Radiology
January 2025
Department of Radiation Oncology, IU Health Cancer Pavilion-University Hospital, 535 Barnhill Dr, RT-041, Indianapolis, IN 46202.
Pre-Radiation Targeted Therapy for Highly Selected Patients with Newly Diagnosed Glioblastoma: New Tricks for an Old Dog?
Neuro Oncol
January 2025
Division of Neuro-Oncology, Department of Neurology, and the Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians & Surgeons and New York-Presbyterian New York, NY, USA.
Patient perspective: Is intensive screening of women at high risk of breast cancer evidence-based medicine or ?
Womens Health (Lond)
January 2025
Department of Pharmacy Practice, Midwestern University College of Pharmacy, Glendale Campus, Glendale, AZ, USA.
In 2023, a breast cancer risk assessment and a subsequent positive test for the BRCA-2 genetic mutation brought me to the uncomfortable intersection of a longstanding career as an advocate for high-quality medical evidence to support shared patient-provider decision making and a new role as a high-risk patient. My search for studies of available risk-management options revealed that the most commonly recommended approach for women with a ⩾20% lifetime breast cancer risk, intensive screening including annual mammography and/or magnetic resonance imaging beginning at age 25-40 years, was supported only by cancer-detection statistics, with almost no evidence on patient-centered outcomes-mortality, physical and psychological morbidity, or quality of life-compared with standard screening or a surgical alternative, bilateral risk-reducing mastectomy. In this commentary, I explore parallels between the use of the intensive screening protocol and another longstanding women's health recommendation based on limited evidence, the use of hormone therapy (HT) for postmenopausal chronic disease prevention, which was sharply curtailed after the publication of the groundbreaking Women's Health Initiative trial in 2002.
View Article and Find Full Text PDFThe role of stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) in locally advanced and borderline resectable pancreatic cancer.
Ann Transl Med
December 2024
Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!